Navigation Links
Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
Date:4/15/2008

AMSTERDAM, April 15 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma announced today that the U.S. Food and Drug Administration (FDA) has granted its product Rhitol(TM) Orphan Drug Designation for the treatment of chronic Graft versus Host Disease (GvHD). This complication of allogeneic bone marrow transplantation is highly disabilitating and can become life threatening when the patient is unresponsive to steroid treatment. Rhitol(TM) has completed a multicenter phase I/II study for patients with severe steroid resistant chronic GvHD. A phase III study is anticipated to start in 2008.

"The decision by the FDA to grant Rhitol(TM) orphan drug designation in this area of blood cancer with unmet medical need advances our efforts to develop an innovative treatment" says Dr. Manja Bouman, Chief Executive Officer of Kiadis Pharma.

The FDA's orphan drug designation is reserved for new therapies being developed to treat diseases or conditions that affect fewer than 200,000 people in the United States. The orphan drug designation provides for an accelerated review process, tax benefits, exemption from user fees and a seven-year period of market exclusivity in the United States after product approval.

About Rhitol(TM)

Rhitol(TM) is under development as a treatment for patients with chronic GvHD resistant or intolerant to immunosuppressive agents. Rhitol(TM) treatment targets activated T cells that cause GvHD and results in immune modulation within patients with chronic GvHD, restores immune tolerance and attempts to achieve disease remission.

About chronic GvHD

GvHD is a condition that can develop after allogeneic bone marrow transplantation and resembles an autoimmune disease. Graft versus Host Disease is caused by immune cells from the donor graft attacking the patient's tissues and organs. Chronic GvHD usually develops some time after the transplantation and is generally treated by immunosuppressive drugs, such as ster
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
3. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
6. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
7. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
8. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
9. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
10. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
11. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... Vt. (PRWEB) August 28, 2014 ... testing around the world is available from Strategic ... diagnostics companies. “ Industrial Microbiology Market Review, Fourth ... Industrial Market ” (IMMR—4) tracks and compares microbiology ... in North America, Europe and Asia, and forecasts ...
(Date:8/28/2014)... PrimeSource Building Products, Inc., a leading ... to support their communication needs with the ... conferencing platform GlobalMeet powered by SoundConnect. The solution ... SoundConnect delivers award winning “results driven” business class ... be utilizing GlobalMeet powered by SoundConnect ...
(Date:8/28/2014)... Whitehouse Laboratories is excited to announce ... PTI Inspection Systems that will enable it ... art leak testing method development and validation programs using ... As part of this agreement, Whitehouse Labs has taken ... Instrument developed and manufactured by PTI. The HVLD ...
(Date:8/27/2014)... (PRWEB) August 27, 2014 Green & ... in Series B funding and secured Otter Capital as ... capital will accelerate commercialization of GGI’s Agriplier™ technology, building ... types. , “Since our first meeting, we have ... the biological product space,” said Alan Sobba, President and ...
Breaking Biology Technology:2 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 22 Billion Industrial Microbiology Tests Conducted for Product Quality and Safety Worldwide 3PrimeSource Chooses SoundConnect as Collaboration Provider 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 2Whitehouse Labs Renews Partnership with PTI Inspection Systems 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3
... Stem Cell Institute,(RSCI) today announced two additions to ... cell research proficiency in the process.,Don Margolis, RSCI ... two,things in common: pioneering stem cell research and ... incurable. Today we add two,Massachusetts researchers, David Matzilevich, ...
... - Company Appoints Charles Rowland to Chief Financial ... ViroPharma Incorporated,(Nasdaq: VPHM ) today announced that ... strengthened its leadership in human resources,clinical development and ... vice president and chief financial officer; Thomas Macnamara ...
... Force ... ANX-514, - Company to Present Updated Corporate Outlook at ... Pharmaceuticals,Inc. (Amex: ANX ) announced today that it has ... towards the,Company,s near term goals. ADVENTRX will focus its resources ...
Cached Biology Technology:RSCI Announces Two Additions to Its Science Advisory Board, Calling for More Stem Cell Research on Diabetes 2ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 2ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 3ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 4ViroPharma Enhances Leadership to Support Global Growth and Expanding Business 5ADVENTRX Announces Restructuring and Cost Reduction Initiatives 2ADVENTRX Announces Restructuring and Cost Reduction Initiatives 3ADVENTRX Announces Restructuring and Cost Reduction Initiatives 4ADVENTRX Announces Restructuring and Cost Reduction Initiatives 5ADVENTRX Announces Restructuring and Cost Reduction Initiatives 6
(Date:8/28/2014)... A new study reports that an expansion of marine ... perform key ecological functions. According to investigators from ... at protecting fish have focused on saving the largest ... species that provide key and difficult-to-replace ecological functions. ... are performed by fish species that also are food ...
(Date:8/28/2014)... Access to Research Careers) Program has announced the travel ... from October 18 22, 2014 in San Diego, ... entry of students, post doctorates and scientists from underrepresented ... and to encourage the participation of young scientists at ... MARC conferred 16 awards totaling $29,600., The FASEB MARC ...
(Date:8/28/2014)... FASEB MARC (Maximizing Access to Research Careers) Program ... Genetics Society of America,s 27th Annual Mouse Molecular ... 2014 in Pacific Grove, California. These awards ... post doctorates and scientists from underrepresented groups into ... to encourage the participation of young scientists at ...
Breaking Biology News(10 mins):Study finds marine protected areas inadequate for protecting fish and ocean ecology 2
... fungi, often found in composts that self-ignite without flame or ... of Myceliophthora thermophila and Thielavia terrestris ... The findings, published in Nature Biotechnology , may ... chemicals and other industrial materials. "Organisms that thrive ...
... release is available in German . They ... model of evolutionary success: viruses. Viruses are extremely adaptable but they ... into suitable host cells. In the case of some viruses, the ... has been known for almost 50 years. We know, for instance, ...
... Spanish . , The cayenne tick has ... in horses in a 2009 Texas outbreak, according to U.S. ... been considered free from the disease since 1978, but sporadic ... Kleberg County, Texas, a mare was presented for veterinary care ...
Cached Biology News:From compost to sustainable fuels: Heat-loving fungi sequenced 2Manipulated gatekeeper: How viruses find their way into the cell nucleus 2Tick responsible for equine piroplasmosis outbreak identified 2
The BD CBA Human Apoptosis Kit can be used to quantitatively measure,cleaved PARP, Bcl-2, and active Caspase-3 protein levels in a single sample. The,Kit performance has been optimized for analysis o...
... Activation of ICE-family proteases/caspases initiates apoptosis in ... Apoptosis Detection Kit provides a simple and ... by flow cytometry in intact cells. ... two aspartate residues linked to rhodamine 110 ...
The PROTEAN II slab gel casting stand is a component of the PROTEAN II XL and xi casting apparatus. It is supplied with gaskets....
... direct antibiotic-based selection system for recombinant identification. ... eliminating the need for costly color screening. ... to 100% accuracy in recombinant selection. pLivSelect ... colony picking. This cloning kit can be ...
Biology Products: